Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses

Yibin Cai, Haichen Song, Jianqiang Ye, Hongxia Shao, Rangarajan Padmanabhan, Troy C. Sutton, Daniel R. Perez

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mass in ovo vaccination with live attenuated viruses is widely used in the poultry industry to protect against various infectious diseases. The worldwide outbreaks of low pathogenic and highly pathogenic avian influenza highlight the pressing need for the development of similar mass vaccination strategies against avian influenza viruses. We have previously shown that a genetically modified live attenuated avian influenza virus (LAIV) was amenable for in ovo vaccination and provided optimal protection against H5 HPAI viruses. However, in ovo vaccination against other subtypes resulted in poor hatchability and, therefore, seemed impractical. In this study, we modified the H7 and H9 hemagglutinin (HA) proteins by substituting the amino acids at the cleavage site for those found in the H6 HA subtype. We found that with this modification, a single dose in ovo vaccination of 18-day old eggs provided complete protection against homologous challenge with low pathogenic virus in 70% of chickens at 2 or 6 weeks post-hatching. Further, inoculation of 19-day old egg embryos with 10 6 EID50of LAIVs improved hatchability to 90% (equivalent to unvaccinated controls) with similar levels of protection. Our findings indicate that the strategy of modifying the HA cleavage site combined with the LAIV backbone could be used for in ovo vaccination against avian influenza. Importantly, with protection conferred as early as 2 weeks post-hatching, with this strategy birds would be protected prior to or at the time of delivery to a farm or commercial operation.

Original languageEnglish (US)
Article number31
JournalVirology Journal
Volume8
DOIs
StatePublished - Jan 25 2011

Fingerprint

Influenza in Birds
Orthomyxoviridae
Vaccination
Hemagglutinins
Viruses
Mass Vaccination
Poultry
Eggs
Birds
Disease Outbreaks
Communicable Diseases
Ovum
Chickens
Industry
Embryonic Structures
Amino Acids
Proteins

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

Cai, Yibin ; Song, Haichen ; Ye, Jianqiang ; Shao, Hongxia ; Padmanabhan, Rangarajan ; Sutton, Troy C. ; Perez, Daniel R. / Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses. In: Virology Journal. 2011 ; Vol. 8.
@article{ec605fbfa83246d2acee31fe188429af,
title = "Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses",
abstract = "Mass in ovo vaccination with live attenuated viruses is widely used in the poultry industry to protect against various infectious diseases. The worldwide outbreaks of low pathogenic and highly pathogenic avian influenza highlight the pressing need for the development of similar mass vaccination strategies against avian influenza viruses. We have previously shown that a genetically modified live attenuated avian influenza virus (LAIV) was amenable for in ovo vaccination and provided optimal protection against H5 HPAI viruses. However, in ovo vaccination against other subtypes resulted in poor hatchability and, therefore, seemed impractical. In this study, we modified the H7 and H9 hemagglutinin (HA) proteins by substituting the amino acids at the cleavage site for those found in the H6 HA subtype. We found that with this modification, a single dose in ovo vaccination of 18-day old eggs provided complete protection against homologous challenge with low pathogenic virus in 70{\%} of chickens at 2 or 6 weeks post-hatching. Further, inoculation of 19-day old egg embryos with 10 6 EID50of LAIVs improved hatchability to 90{\%} (equivalent to unvaccinated controls) with similar levels of protection. Our findings indicate that the strategy of modifying the HA cleavage site combined with the LAIV backbone could be used for in ovo vaccination against avian influenza. Importantly, with protection conferred as early as 2 weeks post-hatching, with this strategy birds would be protected prior to or at the time of delivery to a farm or commercial operation.",
author = "Yibin Cai and Haichen Song and Jianqiang Ye and Hongxia Shao and Rangarajan Padmanabhan and Sutton, {Troy C.} and Perez, {Daniel R.}",
year = "2011",
month = "1",
day = "25",
doi = "10.1186/1743-422X-8-31",
language = "English (US)",
volume = "8",
journal = "Virology Journal",
issn = "1743-422X",
publisher = "BioMed Central",

}

Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses. / Cai, Yibin; Song, Haichen; Ye, Jianqiang; Shao, Hongxia; Padmanabhan, Rangarajan; Sutton, Troy C.; Perez, Daniel R.

In: Virology Journal, Vol. 8, 31, 25.01.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses

AU - Cai, Yibin

AU - Song, Haichen

AU - Ye, Jianqiang

AU - Shao, Hongxia

AU - Padmanabhan, Rangarajan

AU - Sutton, Troy C.

AU - Perez, Daniel R.

PY - 2011/1/25

Y1 - 2011/1/25

N2 - Mass in ovo vaccination with live attenuated viruses is widely used in the poultry industry to protect against various infectious diseases. The worldwide outbreaks of low pathogenic and highly pathogenic avian influenza highlight the pressing need for the development of similar mass vaccination strategies against avian influenza viruses. We have previously shown that a genetically modified live attenuated avian influenza virus (LAIV) was amenable for in ovo vaccination and provided optimal protection against H5 HPAI viruses. However, in ovo vaccination against other subtypes resulted in poor hatchability and, therefore, seemed impractical. In this study, we modified the H7 and H9 hemagglutinin (HA) proteins by substituting the amino acids at the cleavage site for those found in the H6 HA subtype. We found that with this modification, a single dose in ovo vaccination of 18-day old eggs provided complete protection against homologous challenge with low pathogenic virus in 70% of chickens at 2 or 6 weeks post-hatching. Further, inoculation of 19-day old egg embryos with 10 6 EID50of LAIVs improved hatchability to 90% (equivalent to unvaccinated controls) with similar levels of protection. Our findings indicate that the strategy of modifying the HA cleavage site combined with the LAIV backbone could be used for in ovo vaccination against avian influenza. Importantly, with protection conferred as early as 2 weeks post-hatching, with this strategy birds would be protected prior to or at the time of delivery to a farm or commercial operation.

AB - Mass in ovo vaccination with live attenuated viruses is widely used in the poultry industry to protect against various infectious diseases. The worldwide outbreaks of low pathogenic and highly pathogenic avian influenza highlight the pressing need for the development of similar mass vaccination strategies against avian influenza viruses. We have previously shown that a genetically modified live attenuated avian influenza virus (LAIV) was amenable for in ovo vaccination and provided optimal protection against H5 HPAI viruses. However, in ovo vaccination against other subtypes resulted in poor hatchability and, therefore, seemed impractical. In this study, we modified the H7 and H9 hemagglutinin (HA) proteins by substituting the amino acids at the cleavage site for those found in the H6 HA subtype. We found that with this modification, a single dose in ovo vaccination of 18-day old eggs provided complete protection against homologous challenge with low pathogenic virus in 70% of chickens at 2 or 6 weeks post-hatching. Further, inoculation of 19-day old egg embryos with 10 6 EID50of LAIVs improved hatchability to 90% (equivalent to unvaccinated controls) with similar levels of protection. Our findings indicate that the strategy of modifying the HA cleavage site combined with the LAIV backbone could be used for in ovo vaccination against avian influenza. Importantly, with protection conferred as early as 2 weeks post-hatching, with this strategy birds would be protected prior to or at the time of delivery to a farm or commercial operation.

UR - http://www.scopus.com/inward/record.url?scp=78651563272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651563272&partnerID=8YFLogxK

U2 - 10.1186/1743-422X-8-31

DO - 10.1186/1743-422X-8-31

M3 - Article

C2 - 21255403

AN - SCOPUS:78651563272

VL - 8

JO - Virology Journal

JF - Virology Journal

SN - 1743-422X

M1 - 31

ER -